ERBB2 and breast carcinoma: Studies on breast cancer cell lines have revealed that the rapamycin analogue CCI-779 was most effective in inhibiting growth in cell lines that were ER-dependent, that overexpressed HER-2 and/or had PTEN deletions, and that expressed high levels of activated Akt (Carraway and Hidalgo, 2004).